Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02247388
Other study ID # 1211011052
Secondary ID R01AA022083-01A1
Status Completed
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date April 30, 2020

Study information

Verified date April 2022
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To study the efficacy of AB-CASI against standard of care in a randomized controlled trial in the Emergency Department.


Description:

The research team will rigorously test the efficacy of AB-CASI, against a standard condition (SC) in a first-of-a-kind ED randomized controlled trial. Studying an urban adult (≥ 18 y/o) Latino ED population, the objectives are to demonstrate the superiority of AB-CASI compared to SC in: 1) reduction of alcohol consumption (Aims 1), 2) reduction of negative health behaviors and consequences (Aim 2), and 3) increasing 30-day treatment engagement (Aim 3). The investigators will also explore variation of the AB-CASI intervention on alcohol consumption, alcohol-related negative health behaviors and consequences, and 30-day treatment engagement by Latino subpopulations (Puerto-Rican, Mexican-American, Cuban-American, South/Central American) as well as other potential modifiers (age, birthplace, gender, preferred language, reason for ED visit, and smoking status). English and Spanish speaking Latino adults presenting to the Bridgeport Hospital ED will be screened using the study inclusion and exclusion criteria. In March 2020, the primary and secondary outcomes were corrected to reflect the protocol as it was written initially. The citations section of this study registration also includes the citation for the published protocol manuscript.


Recruitment information / eligibility

Status Completed
Enrollment 840
Est. completion date April 30, 2020
Est. primary completion date April 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - English and Spanish speaking adult - = 18 y/o - Latino patients who present to the Bridgeport Hospital's ED - Drink over the NIAAA low-risk limits. Exclusion Criteria: - Primary language other than English or Spanish - Current enrollment in an alcohol or substance abuse treatment program - Current ED visit for acute psychosis - Condition that precludes interview or AB-CASI use i.e., life threatening injury/illness - In police custody - Inability to provide two contact numbers for follow-up

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Computerized Alcohol Screening
iPad based automated alcohol screening
Brief Negotiated Interview
iPad based automated brief negotiated interview (BNI)

Locations

Country Name City State
United States Bridgeport Hospital Bridgeport Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Vaca FE, Dziura J, Abujarad F, Pantalon MV, Hsiao A, Field CA, D'Onofrio G. Trial study design to test a bilingual digital health tool for alcohol use disorders among Latino emergency department patients. Contemp Clin Trials. 2020 Sep;96:106104. doi: 10.1016/j.cct.2020.106104. Epub 2020 Aug 7. Corrected and republished in: Contemp Clin Trials. 2020 Sep 16;:106128. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other 30 Day Treatment Engagement Engagement in alcohol treatment program based on Treatment Services Review at 30 day phone follow up 30 days post enrollment
Primary Self Reported Binge Drinking Episodes Self reported number of binge drinking episodes over the previous 28 days assessed using the 28 day timeline follow back at 12 months.
This outcome was corrected 3/2020 to accurately reflect the time frame from the original protocol.
12 months
Secondary Mean Number of Weekly Drinks Self reported mean number of weekly drinks as measured by a 28 day timeline follow back.
This outcome was corrected 3/2020 to accurately reflect the time frame from the original protocol. It was also moved to the secondary outcome measure section as was the original intent.
12 months post enrollment
Secondary Alcohol-Related Negative Health Behaviors and Consequences: episodes of impaired drivin Self reported alcohol-related negative health behaviors and consequences based on the Brief Event Data survey (includes episodes of impaired driving, riding with an impaired driver, injuries, arrests, tardiness and days absent from work/school) 12 months post enrollment
Secondary Alcohol-Related Negative Health Behaviors and Consequences: episodes riding with an impaired driver Self reported alcohol-related negative health behaviors and consequences based on the Brief Event Data survey (includes episodes of impaired driving, riding with an impaired driver, injuries, arrests, tardiness and days absent from work/school) 12 months post enrollment
Secondary Alcohol-Related Negative Health Behaviors and Consequences: number of injuries Self reported alcohol-related negative health behaviors and consequences based on the Brief Event Data survey (includes episodes of impaired driving, riding with an impaired driver, injuries, arrests, tardiness and days absent from work/school) 12 months post enrollment
Secondary Alcohol-Related Negative Health Behaviors and Consequences: number of arrests Self reported alcohol-related negative health behaviors and consequences based on the Brief Event Data survey (includes episodes of impaired driving, riding with an impaired driver, injuries, arrests, tardiness and days absent from work/school) 12 months post enrollment
Secondary Alcohol-Related Negative Health Behaviors and Consequences: episodes of tardiness from work/school Self reported alcohol-related negative health behaviors and consequences based on the Brief Event Data survey (includes episodes of impaired driving, riding with an impaired driver, injuries, arrests, tardiness and days absent from work/school) 12 months post enrollment
Secondary Alcohol-Related Negative Health Behaviors and Consequences: days absent from work/school Self reported alcohol-related negative health behaviors and consequences based on the Brief Event Data survey (includes episodes of impaired driving, riding with an impaired driver, injuries, arrests, tardiness and days absent from work/school) 12 months post enrollment
See also
  Status Clinical Trial Phase
Completed NCT02901041 - Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism Phase 3
Completed NCT03340051 - Remote Alcohol Monitoring and Episodic Thinking N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Completed NCT02705898 - Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women N/A
Completed NCT02486900 - Neurofeedback & Alcohol Dependence N/A
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02197598 - Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use Phase 4
Recruiting NCT02385643 - The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients N/A
Completed NCT01828866 - Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT01342549 - Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Phase 3
Completed NCT02193204 - Chronic Alcohol, Stress Inflammatory Response and Relapse Risk N/A
Completed NCT01176591 - HBPL Study of the Impact of the NK1 Antagonist Aprepitant Phase 2
Completed NCT01165541 - A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency Phase 2
Completed NCT01056484 - Mindfulness Meditation for Health Phase 2
Completed NCT00585780 - Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse Phase 1/Phase 2
Completed NCT00607620 - Disseminating Organizational SBI Services at Trauma Centers N/A
Completed NCT00884884 - Aripiprazole and Topiramate on Free-Choice Alcohol Use Phase 2/Phase 3
Completed NCT00463346 - Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism Phase 3